Exposure to GLP-1 Medications During Pregnancy
Approximately 1 in 300 women encounter GLP-1 medications during pregnancy, according to the American College of Obstetricians and Gynecologists (ACOG). However, data on the impact of these weight-loss drugs on pregnancy or the fetus is not yet clear.
Guidance from ACOG
In response to lawsuits and emerging studies, ACOG released guidance recommending that patients stop using GLP-1 medications one to two months before conceiving. The organization advises mothers who use GLP-1s while breastfeeding to monitor their infant’s neonatal weight gain closely. Furthermore, ACOG advises against using these medications while breastfeeding preterm infants.
Research Findings and Recommendations
Current studies do not indicate a significant risk of congenital issues from using GLP-1s before or during pregnancy, according to ACOG. Nonetheless, there is limited safety data available to draw definitive conclusions. While it appears GLP-1s do not pass into human milk, factors like obesity and malnutrition could affect breast milk composition. ACOG advises parents using GLP-1s postpartum to create a care plan with their physician.
ACOG’s guidance authors, including Yvette LaCoursiere from the University of California, San Diego, suggest proceeding with caution until more data becomes available. LaCoursiere emphasizes the rapidly evolving nature of this research area and the necessity for ongoing reassessment.
